The increasing complexity of drugs — including vaccines, biologics, sterile injectables and cell therapies — brings pharmaceutical companies significant manufacturing challenges during the pandemic. In turn, this complexity drives supply chain disruptions and changes to business and operational processes to accommodate social distancing, remote working and quarantining. Some pharmaceutical manufacturers have prioritized the manufacture of…